Alan Chapman White

Title: Alan Chapman White: Innovator in Antidepressant Compounds

Introduction

Alan Chapman White is a notable inventor based in Windsor, England. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with antidepressant activity. His work has implications for mental health treatment and showcases the importance of innovation in medicine.

Latest Patents

Alan Chapman White holds a patent for Diazepino[1,2-.alpha.]indoles. This invention relates to bases of a specific formula and their acid addition salts with pharmaceutically acceptable acids. In this formula, R.sup.1 represents phenyl or phenyl substituted by one or more hydroxyl, lower alkyl, lower alkoxy, haloloweralkyl, or halogen atoms. R.sup.2 and R.sup.5 can be hydrogen, hydroxyl, lower alkyl, lower alkoxy, haloloweralkyl, or halogen, while R.sup.3 and R.sup.4 are hydrogen or lower alkyl. The compounds developed from this patent exhibit antidepressant activity, highlighting their potential therapeutic benefits.

Career Highlights

Alan Chapman White is associated with John Wyeth Brother, Limited, where he has contributed to various research initiatives. His work in the pharmaceutical industry has been instrumental in advancing the understanding and treatment of mental health disorders.

Collaborations

Alan has collaborated with Robin Michael Black, further enhancing the research and development efforts in their field.

Conclusion

Alan Chapman White's innovative work in the development of antidepressant compounds demonstrates the critical role of inventors in advancing healthcare solutions. His contributions continue to impact the pharmaceutical landscape positively.